Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Erika Carmel-TechXTAE:ERKA 36 PB Ratio is 2.07 as of Aug. 13, 2026, which is 45% above its 10-year median of 1.43. GuruFocus rates XTAE:ERKA with a GF Score™ of 36/100 and a GF Value™ of ₪0.55 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 784 Medical Devices & Instruments companies, Erika Carmel-Tech ranks better than 51.15% on this metric.
The historical rank and industry rank for Erika Carmel-Tech's PB Ratio or its related term are showing as below:
XTAE:ERKA'
s PB Ratio Range Over the Past 10 Years
Min: 0.14 Med: 1.43 Max: 87.07
Current: 2.07
During the past 8 years, Erika Carmel-Tech's highest PB Ratio was 87.07. The lowest was 0.14. And the median was 1.43.
XTAE:ERKA's PB Ratio is ranked better than 51.15% of 784
companies
in the Medical Devices & Instruments industry
Industry Median: 2.11
vs XTAE:ERKA: 2.07
During the past 12 months, Erika Carmel-Tech's average Book Value Per Share Growth Rate was -34.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -14.60% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Erika Carmel-Tech was 139.00% per year. The lowest was -44.60% per year. And the median was -0.45% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Erika Carmel-Tech PB Ratio Related Terms
Erika Carmel-Tech PB Ratio Historical Data
* Premium members only.
The historical data trend for Erika Carmel-Tech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Erika Carmel-Tech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Erika Carmel-Tech PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Erika Carmel-Tech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Erika Carmel-Tech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Erika Carmel-Tech (XTAE:ERKA) has a PB Ratio of 2.07 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Erika Carmel-Tech and its competitors. This is 45% above median its historical median of 1.43. Over the past decade, Erika Carmel-Tech's PB Ratio has ranged from 0.14 to 87.07. According to the industry distribution chart, Erika Carmel-Tech ranks #383 out of 784 companies in the Medical Devices & Instruments industry, placing it in the top 48.9%.
Is Erika Carmel-Tech's PB Ratio too high?
Erika Carmel-Tech's current PB Ratio of 2.07 is 45% above median its 10-year median of 1.43. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 87.07. The Medical Devices & Instruments industry median PB Ratio is 2.11. Erika Carmel-Tech's value of 2.07 is 1.9% below this industry median. Based on the distribution chart, Erika Carmel-Tech ranks #383 out of 784 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Erika Carmel-Tech has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Erika Carmel-Tech's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Erika Carmel-Tech ranks #383 out of 784 companies for PB Ratio. This puts Erika Carmel-Tech in the upper half of its industry. The industry median PB Ratio is 2.11. Erika Carmel-Tech's value of 2.07 is 1.9% below this benchmark. Historically, Erika Carmel-Tech's own PB Ratio has ranged from 0.14 to 87.07 over the past decade. While the company's 10-year median is 1.43 vs. the industry median of 2.11, Erika Carmel-Tech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.11, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Erika Carmel-Tech's current PB Ratio of 2.07 is 1.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Erika Carmel-Tech and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Erika Carmel-Tech's current PB Ratio is 2.07, which is 45% above median its own 10-year median of 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Erika Carmel-Tech stock overvalued right now?
Based on GuruFocus' analysis, Erika Carmel-Tech (XTAE:ERKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪0.55, compared to a current price of ₪0.49 — trading 11.6% below its estimated fair value. The current PB Ratio is 2.07, which is 45% above median its 10-year median of 1.43 and 1.9% below the Medical Devices & Instruments industry median of 2.11. Erika Carmel-Tech's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Erika Carmel-Tech (XTAE:ERKA), the current PB Ratio is 2.07 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Erika Carmel-Tech (XTAE:ERKA) Overvalued in 2026?
Based on GuruFocus' analysis, Erika Carmel-Tech stock appears to be undervalued.
The current stock price of ₪0.49 is trading 11.6% below its estimated GF Value™ of ₪0.55.
GuruFocus considers Erika Carmel-Tech to be Modestly Undervalued.
Key valuation signals for XTAE:ERKA:
PB Ratio: 2.07 (45% above median its 10-year median of 1.43)
GF Value™: ₪0.55 vs. price of ₪0.49 (11.6% below fair value)
Industry Position: 1.9% below the Medical Devices & Instruments median (#383 of 784)
No single metric tells the full story. See the XTAE:ERKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Erika Carmel-Tech Ltd Formerly Erika B-Cure Laser Ltd is engaged in the development and production of laser devices for the treatment of pain and wounds. Its devices provide treatment for Knee Pain, Lower Back Pain, Neck Pain, Shoulder Pain, Finger Joint pain, and Burns.
36GF Score
Get the complete analysis for XTAE:ERKA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:ERKA has been successfully added to your 
